Incannex Healthcare Inc. (NASDAQ:IXHL) shares jumped 10% after the company announced encouraging Phase 2 trial results for ...

Incannex Healthcare (IXHL) stock falls even as the company's lead asset IHL-42X achieves success in a Phase 2 trial for sleep ...

Incannex Healthcare Inc. (NASDAQ:IXHL) saw its stock jump 10% on Friday after positive Phase 2 trial results for its ...

Incannex's IHL-42X showed significant efficacy in Phase 2 sleep apnea trial, with strong AHI reduction, improved sleep, and ...

--Incannex Healthcare Inc.,, a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient ...

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company ...

Incannex Chief Scientific Officer, Dr Mark Bleackley said: “It is an exciting milestone for us to complete dosing in our Phase 1 study on IHL-675A because it has so many potential therapeutic uses.

Incannex’s reports filed with the U.S. Securities and Exchange Commission (SEC) including its annual report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on September ...

--Incannex Healthcare Inc.,, a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced that it has entered into security purchase ...

Incannex Healthcare Limited IXHLIHLcompleted a pre-investigational new drug application ('pre-IND') meeting with the U.S. Food and Drug Administration to discuss the development IHL-42X.

Incannex still hasn't announced the start of clinical studies with IHL-42X in the U.S. While it could soar further, it's probably best to keep this stock on a watch list until it can report ...

Incannex's reports filed with the U.S. Securities and Exchange Commission (SEC) including its annual report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on September 30 ...